Loading...
ASH congresses2024-03-13T17:09:48+01:00

ASH 2023 – hybrid

Lecture Board: Othman Al-Sawaf, MD; Jorge J. Castillo, MD; Chan Cheah, MD; Francesca M. Gay, MD, PhD; Anath C. Lionel, MD, PhD; Paolo Strati, MD; Jason Westin, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASH 2023

ASH 2023 - Slidekit

Slidekit BTKi and Bcl2i in CLL

Full report (english)

EXPERT VIDEOS

All video interviews from ASH 2023

Barbara F. Eichhorst describes possible approaches to improve the early detection of molecular CLL relapses, discusses venetoclax-based first-line combinations in CLL, and rates the relative efficacy and safety of different BTK inhibitors in relapsed/refractory CLL while finally sharing her personal highlights from the ASH 2023 congress.

Ramón García-Sanz gives insights into the assessment of residual disease in multiple myeloma and explains future clinical implications of these data. Moreover, he discusses in which ways the evaluation of minimal residual disease might improve the management of patients with Waldenström macroglobulinemia and shares his personal highlight from the ASH 2023 congress.

Stephan Stilgenbauer discusses the current evidence regarding the treatment of Richter transformation with modern agents and reviews the findings of the RT1 trial presented at the ASH 2023 meeting. Finally, he highlights future combinations of novel agents like adding the next-generation BCL-2 inhibitor sonrotoclax to tislelizumab plus zanubrutinib which will be investigated in the amendment of the RT1 trial or the use of the non-covalent BTK inhibitor pirtobrutinib combined with epcoritamab, a bispecific antibody, that will be in the focus of the international RT2 trial.

ASH 2022 – hybrid

Lecture Board: Othman Al-Sawaf, MD; Chan Cheah, DMSc; Alex F. Herrera, MD; Elisabeth Koller, MD; Constantine Tam, MBBS, MD; Stefan Vogt, MD; Michael Wang, MD; Moshe Yair Levy, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASH 2022

ASH 2021 virtual - Slidekit

Slidekit BTK inhibition and BCL2 inhibition in B-cell malignancies and AML

ASH 2022 hybrid - Congress Report

Full report (english)

EXPERT VIDEOS

All video interviews from ASH 2022

Shirley D’Sa discusses the results of the first clinical trial investigating checkpoint inhibition in relapsed/refractory Waldenström’s macroglobulinemia as well as other immunotherapeutic agents or combinations that might be worth investigating in this setting and explains the association of type I cryoglobulinemia with WM, IgM monoclonal gammopathy of undetermined significance or non-Hodgkin Lymphoma.

ASH 2021 – virtual

Lecture Board: Othman Al-Sawaf, MD; Jorge J. Castillo, MD; Wojciech Jurczak, MD, PhD; Amitkumar Mehta, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASH 2021

ASH 2021 virtual - Slidekit

Slidekit BTK inhibition and BCL2 inhibition in CLL/SLL and other B-cell malignancies

ASH 2021 virtual - Congress Report

Full report (english)

EXPERT VIDEOS

All video interviews from ASH 2021

Constantine Tam gives an overview of the results obtained by the SEQUOIA trial, the advantages and disadvantages of BTKi and BCL2i 1L therapy versus their drawbacks and explains which CLL-patients might benefit from BTK inhibitor monotherapy and who might be better off receiving combination treatment including a BTK inhibitor and how novel BCL2 inhibitors improve CLL treatment compared to the standard agent venetoclax.

Jennifer A. Woyach explains which factors need to be considered when choosing the frontline regimen for patients with early-stage CLL, how resistance to BTK inhibition can be tackled in later lines, if chemoimmunotherapy still has a role in the treatment of CLL and highlights the most interesting findings on the management of treatment-naïve CLL patients.

 

Paolo Ghia highlights what modern targeted agents can achieve in terms of undetectable minimal residual disease in the management of patients with CLL and important methodological recommendations to ensure correct assessment of TP53 and IGHV mutational status. He explains how the three epigenetic subgroups (m-CLL, n-CLL, i-CLL) are related, what effect a thorough immunogenetic analysis has on the risk stratification of patients with CLL and gives an overview about the most interesting findings on the management of pretreated CLL patients.

Alessandra Tedeschi depicts her personal highlights reported at ASH 2021 and explains the results obtained in treatment-naïve CLL patients with a deletion of 17p in the SEQUOIA study. The influence of age, fitness, and concomitant medications on the management and outcomes of patients with CLL treated with targeted agents, the most notable progress in B-cell malignancies over the last years and the role of BTK inhibitors in the treatment of patients with Waldenström’s macroglobulinemia are summarized, too.

ASH 2020 – virtual

Lecture Board: Paul Barr, MD; Chan Cheah, MBBS; Paolo Ghia, MD, PhD; Preetesh Jain, MD, PhD; Stephen Opat, MD; Kerry Rogers, MD; Alessandra Tedeschi, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASH 2020

ASH 2020 virtual - Slidekit

Slidekit BTK inhibition in B-Cell Malignancies

ASH 2020 virtual - Congress Report

Full report (english)

EXPERT VIDEOS

All video interviews from ASH 2020

Steven P. Treon explains about innovative approaches in the treatment of Waldenström’s macroglobulinemia, future aspects and the successful use of BTK inhibition within niche groups of patients with WM, and potential benefits of BTK inhibitors regarding COVID-19 complications.

Jorge Castillo relates to recent developments with respect to follicular lymphoma, multiple myeloma and Waldenström’s macroglobulinemia, current insights into CAR-T cell therapy in the setting of multiple myeloma, and the future of anti-CD38 antibody treatment in patients with Waldenström’s macroglobulinemia.

Alessandra Tedeschi summarizes the results from the MAGNOLIA and iNNOVATE trials, relates to recent advances in the management of marginal zone lymphoma and discusses the effect of the introduction of BTK inhibition on the prognosis of patients with Waldenström’s macroglobulinemia.

Stephen Opat discusses the requirements for treatment-free long-term remission in the setting of CLL and talks about the future of BTK inhibitors and promising combinations in B-cell malignancies in general, as well as the strengths and limitations of immune checkpoint inhibitors.

Go to Top